Pre-merger rules change in US - Preserving competition or burdening biopharma?
This article was originally published in SRA
Many more licensing agreements among drug makers could come under US antitrust review – about 30 more transactions per year – if a newly proposed change in the reporting rules is adopted, which could mean added scrutiny, fees potentially up to $280,000, an additional waiting period to seal a deal and more paperwork for biopharma firms1.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.